blog

Latest from the Quantamize Blog

End of Day Market Update

Jun 18, 2018

US Markets End of Day Snapshot

US stocks failed to find direction, and finished trading mixed, with the S&P 500 -0.21%, and the Dow Jones Industrial -0.41%, while the Russell 2000 rose 0.51%, and the Nasdaq Composite edged 0.01% higher. The S&P 500 was led lower by telecommunications services (-1.97%), consumer staples (-1.48%), and healthcare stocks (-0.99%), while energy (+1.12%), utilities (+0.35%), and information technology stocks (+0.26%) were the biggest outperformers. The VIX rose 30 basis points to 12.32. The most actively traded options in US markets today were VIX June 20 ATM and OTM Puts, EEM July 20 OTM Puts, BAC June 22 ATM Calls, and EFA July 20 OTM Puts. Yield on the US 10-year fell 0.5 basis points to 2.915%. The USD$ index is down 1 basis point, as losses in the AUD$ and GBP£ were offset by gains in the CHF, JPY¥, and EUR€.

*Data in Price Return, Source: Stockdio

S&P 500 Sector ETFs - End of Day

*Data in Price Return, Source: Stockdio

Russell 1000 Factor ETFs - End of Day

*Data in Price Return, Source: Stockdio

Stocks Trending in the News

Click name for Q-Factor rating and financial data.

Colgate-Palmolive (CL) has announced a $5 billion share repurchase program and has also announced a quarterly dividend of $0.42 per share. Shares of Colgate Palmolive are up 1.09% to $64.00 post-market, after trading 2.19% lower in today’s trading

FleetCor Technologies (FLT) finished trading 6.45% higher today, after it was announced that the company would be replacing Time Warner Cable (TWX) in the S&P 500

Fujifilm (4901 JP) is suing Xerox Corp (XRX) for $1 billion, and is accusing the company of giving in to the demands of investors Carl Icahn and Darwin Deason

Valeant Pharmaceuticals International Inc (VRX) stock closed 12.35% lower today, after it was reported that FDA regulators have rejected the company’s application for a new plaque psoriasis lotion, called Duobrii. Valeant management had viewed Duobrii as the company’s first new drug to come to market in years